Format

Send to

Choose Destination
Cell Stem Cell. 2016 Feb 4;18(2):174-88. doi: 10.1016/j.stem.2016.01.012.

Stem and Progenitor Cell-Based Therapy of the Central Nervous System: Hopes, Hype, and Wishful Thinking.

Author information

1
Center for Translational Neuromedicine and the Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA; Center for Basic and Translational Neuroscience, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen 2200, Denmark. Electronic address: steven_goldman@urmc.rochester.edu.

Abstract

A variety of neurological disorders are attractive targets for stem and progenitor cell-based therapy. Yet many conditions are not, whether by virtue of an inhospitable disease environment, poorly understood pathophysiology, or poor alignment of donor cell capabilities with patient needs. Moreover, some disorders may be medically feasible targets but are not practicable, in light of already available treatments, poor risk-benefit and cost-benefit profiles, or resource limitations. This Perspective seeks to define those neurological conditions most appropriate for cell replacement therapy by considering its potential efficacy and clinical feasibility in those disorders, as well as potential impediments to its application.

KEYWORDS:

astrocyte; cell therapy; glial progenitor cell; myelin disease; neural stem cell; neurodegenerative disease; neurological therapeutics; oligodendrocyte progenitor cell

PMID:
26849304
PMCID:
PMC5310249
DOI:
10.1016/j.stem.2016.01.012
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center